Tags

Type your tag names separated by a space and hit enter

A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity.
Arch Intern Med. 1992 May; 152(5):961-6.AI

Abstract

BACKGROUND

Congressional hearings initiated in March 1990 revealed that America's $10 billion a year weight loss industry is subject to minimal regulation by federal agencies. Consumers are forced to rely on advertisements and testimonials when selecting treatment because no proprietary program has provided a prospective assessment of its short- and long-term results of treatment. This report describes such an assessment.

METHODS

A total of 517 obese patients (407 women and 110 men) participated in a proprietary program that included 12 weeks of treatment by very-low-calorie diet within a 26-week program of life-style modification. Patients were treated in two cohorts (6 months apart) according to a standardized protocol implemented at 18 hospital-based clinics across the nation.

RESULTS

Fifty-six percent of women and 54% of men completed treatment, at which time their weight losses (mean +/- SEM) were 22.0 +/- 0.6 and 32.1 +/- 1.4 kg, respectively. Weight losses of women and men who discontinued treatment averaged 14.3 +/- 0.7 and 20.0 +/- 1.6 kg, respectively. Weight loss was associated with significant improvements in blood pressure and total serum cholesterol levels. A 1-year follow-up evaluation of 74% of patients in the second cohort who completed treatment revealed that they maintained 15.3 +/- 1.2 of their 24.8 +/- 1.0-kg end-of-treatment weight loss; 59% of patients maintained a loss of 10 kg or more.

CONCLUSION

We hope that this report will lead to the systematic evaluation of other proprietary weight loss programs and to the publication of findings that will permit consumers to make informed treatment decisions.

Authors+Show Affiliations

Center for Health and Behavior, Syracuse University, NY 13244.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

1580722

Citation

Wadden, T A., et al. "A Multicenter Evaluation of a Proprietary Weight Reduction Program for the Treatment of Marked Obesity." Archives of Internal Medicine, vol. 152, no. 5, 1992, pp. 961-6.
Wadden TA, Foster GD, Letizia KA, et al. A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity. Arch Intern Med. 1992;152(5):961-6.
Wadden, T. A., Foster, G. D., Letizia, K. A., & Stunkard, A. J. (1992). A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity. Archives of Internal Medicine, 152(5), 961-6.
Wadden TA, et al. A Multicenter Evaluation of a Proprietary Weight Reduction Program for the Treatment of Marked Obesity. Arch Intern Med. 1992;152(5):961-6. PubMed PMID: 1580722.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity. AU - Wadden,T A, AU - Foster,G D, AU - Letizia,K A, AU - Stunkard,A J, PY - 1992/5/1/pubmed PY - 1992/5/1/medline PY - 1992/5/1/entrez SP - 961 EP - 6 JF - Archives of internal medicine JO - Arch Intern Med VL - 152 IS - 5 N2 - BACKGROUND: Congressional hearings initiated in March 1990 revealed that America's $10 billion a year weight loss industry is subject to minimal regulation by federal agencies. Consumers are forced to rely on advertisements and testimonials when selecting treatment because no proprietary program has provided a prospective assessment of its short- and long-term results of treatment. This report describes such an assessment. METHODS: A total of 517 obese patients (407 women and 110 men) participated in a proprietary program that included 12 weeks of treatment by very-low-calorie diet within a 26-week program of life-style modification. Patients were treated in two cohorts (6 months apart) according to a standardized protocol implemented at 18 hospital-based clinics across the nation. RESULTS: Fifty-six percent of women and 54% of men completed treatment, at which time their weight losses (mean +/- SEM) were 22.0 +/- 0.6 and 32.1 +/- 1.4 kg, respectively. Weight losses of women and men who discontinued treatment averaged 14.3 +/- 0.7 and 20.0 +/- 1.6 kg, respectively. Weight loss was associated with significant improvements in blood pressure and total serum cholesterol levels. A 1-year follow-up evaluation of 74% of patients in the second cohort who completed treatment revealed that they maintained 15.3 +/- 1.2 of their 24.8 +/- 1.0-kg end-of-treatment weight loss; 59% of patients maintained a loss of 10 kg or more. CONCLUSION: We hope that this report will lead to the systematic evaluation of other proprietary weight loss programs and to the publication of findings that will permit consumers to make informed treatment decisions. SN - 0003-9926 UR - https://www.unboundmedicine.com/medline/citation/1580722/A_multicenter_evaluation_of_a_proprietary_weight_reduction_program_for_the_treatment_of_marked_obesity_ DB - PRIME DP - Unbound Medicine ER -